ArticlePloS one2014
Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 73 citations in OpenAlex.
- Interleukin-37 Serum Levels in Oral Squamous Cell Carcinoma.Journal of dentistry (Shiraz, Iran) · 2026Article
- Brain fatigue in Graves' disease: symptoms and presentation of a possible mechanism at the cellular level.European thyroid journal · 2026Review
- The Potential Contribution of the IL-37/IL-18/IL-18BP/IL-18R Axis in the Pathogenesis of Sjögren's Syndrome.International journal of molecular sciences · 2025Article
- Interleukin-37 reduces lipopolysaccharide induced matrix metalloproteinase-9 in gingival epithelial cells.BMC oral health · 2025Article
- COVID-19 vaccine-induced autoimmune hyperthyroidism: Graves' disease.Frontiers in immunology · 2025Review
- Uncoupled pyroptosis and IL-1β secretion downstream of inflammasome signaling.Frontiers in immunology · 2023Review
- Recombinant IL-37 Exerts an Anti-inflammatory Effect on Human Aortic Valve Interstitial Cells through Extracellular and Intracellular Actions.International journal of biological sciences · 2023Article
- Evaluation of interleukins 37 and 38 and vitamin D status in the serum of women with Graves' disease.Journal of clinical laboratory analysis · 2022Article
- The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases.Advances in therapy · 2022Review
- Decreased serum interleukin-41/Metrnl levels in patients with Graves' disease.Journal of clinical laboratory analysis · 2022Article
- Low levels of serum IL-39 are associated with autoimmune thyroid disease.Journal of clinical laboratory analysis · 2022Article
- The characteristics and clinical significance of elevated serum IgG4/IgG levels in patients with Graves' disease.Endocrine · 2022Observational
- Interleukin-1 in Coronary Artery Disease.Current topics in medicinal chemistry · 2022Article
- Circulating Interleukin-37 Levels in Healthy Adult Humans - Establishing a Reference Range.Frontiers in immunology · 2021Article
- Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities.Nature communications · 2020Article
- Interleukin‑37 is increased in peripheral blood mononuclear cells of coronary heart disease patients and inhibits the inflammatory reaction.Molecular medicine reports · 2020Article
- In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod.Molecules (Basel, Switzerland) · 2019Article
- IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Plasma levels and expression of interleukin-37 in patients with immune thrombocytopenia.Experimental and therapeutic medicine · 2019Article
- Mast Cells May Regulate The Anti-Inflammatory Activity of IL-37.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-37 (IL-37), a member of IL-1 family, is primarily an anti-inflammatory cytokine, which reduces systemic and local inflammation. However, the expression and role of IL-37 in Graves' disease (GD) remains unknown. This study aims to measure the levels of serum and peripheral blood mononuclear cells (PBMCs) IL-37 in patients with Graves' disease and to examine its association with disease activity. Furthermore, we investigate the effect of IL-37 on proinflammatory cytokines involved in the pathogenesis of GD.
methodsThe expressions of IL-37, TNF-α, IL-6, and IL-17 mRNA in peripheral blood mononuclear cells (PBMCs) of 40 patients with Graves' disease were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR), and the levels of IL-37, TNF-α, IL-6, and IL-17 in serum were detected by enzyme-linked immunoassay (ELISA). The correlation of serum IL-37 levels with cytokines and disease activity in Graves' disease patients were investigated. The expressions of cytokines TNF-α, IL-6, and IL-17 in PBMCs under recombinant IL-37 stimulation were determined by RT-PCR and ELISA respectively.
resultsThe levels of IL-37, TNF-α, IL-6, and IL-17 in PBMCs and serum were significantly increased in patients with GD compared with healthy controls (HC). Serum IL-37 were closely correlated with TNF-α, IL-6, IL-17, thyrotropin (TSH), free thyroxine (FT4),free triiodothyronine (FT3) and thyrotropin receptor antibody (TRAB). GD patients with active disease showed higher IL-37 mRNA and serum protein levels compared with those with inactive disease as well as HC. Moreover, IL-37 suppressed the production of IL-6, IL-17 and TNF-α in PBMCs of patients with GD.
conclusionsIncreased level of IL-37 in patients with GD are associated with TNF-α, IL-6, IL-17 and disease activity, and it plays a protective role against inflammatory effect in GD by inhibiting the production of proinflammatory cytokines. Thus, IL-37 may provide a novel research target for the pathogenesis and therapy of GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.